<DOC>
	<DOCNO>NCT00664339</DOCNO>
	<brief_summary>We evaluate preventive impact vaccination subsequent death event 117 severe congestive heart patient require ventilator support without endotracheal intubation aggressive medical therapy . They randomly allocate single-blind manner unique intramuscular influenza vaccination control . The first primary outcome evaluate 6 month follow-up - cardiovascular death - occur 3 % patient vaccine group Vs 17 % control ( p=0.022 ) . The composite end point occur 33 % patient vaccine group Vs 74 % control group , p = &lt; 0.001 .</brief_summary>
	<brief_title>Flu Vaccination Congestive Heart Failure</brief_title>
	<detailed_description>Background : Recent report detect one barrier vaccination influenza infection , physicians strongly recommend application cardiovascular patient risk . We evaluate preventive impact vaccination death severe congestive heart failure hospitalize patient . Methods Results : A total 117 severe congestive heart failure patient ( New York Heart Association class III IV ) admit first 12 hour require ventilator support without endotracheal intubation high dos loop-diuretics , include prospective , multicenter log , winter season . Congestive heart patient receive intravenous vasodilator loop-diuretics plus standard therapy , randomly allocate single-blind manner unique intramuscular influenza vaccination control . Death , combine end point ( death , re-hospitalization reason ) assess 6 month follow-up . The first primary outcome - cardiovascular death - occur 3 % patient vaccine group Vs 17 % control ( odds ratio vaccine compare control : 0.16 ; 95 percent confidence interval , 0.33 0.79 ; p=0.022 ) . The composite end point occur 33 % patient vaccine group Vs 74 % control , p = &lt; 0.001 . The need add inotropic drug occur 8 % patient receive vaccination , 12.5 % control group .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male female patient 's &gt; 21 year age severe congestive heart failure ( New York Heart Association class III IV ) require immediate administration intravenous vasodilator drug , oxygen therapy , less 160 mg intravenous furosemide eligible inclusion . Definite evidence underlie heart failure also require show least two follow : ) Orthopnea admission b ) Xray show evidence elevate wedge pressure indicate congestive heart failure c ) recent prior hospitalization ( within 30 day prior index hospitalization ) congestive heart failure episode ) echocardiography data show poor leave ventricular ejection fraction ( 0.40 low measuring biplane Simpson 's method e ) noninvasive ventilation maintenance SaO2 90 % f ) wet rale least low half lung field Patients final diagnosis Congestive Heart Failure consequence necrotic chronic ischemic heart disease , infective origin chronic Chagas Disease , chronic valvular heart disease ( surgically repair ) , idiopathic origin also include present study Patients concomitant infective disease exclude study Patients evidence evolve multi organic failure ( hepatic renal dysfunction require dialysis ) , terminal disease , impede cause followup , include contraindication vaccination , exclude study Those congestive heart failure follow unstable coronary artery disease , prior bypass surgery , angioplasty congestive heart failure complicate myocardial infarction require urgent intervention exclude also Those individual require mechanical ventilation admission Patients prior vaccination also exclude Pregnancy condition exclusion criterion Those patient unable refuse give write inform consent also exclude present study</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Heart failure ,</keyword>
	<keyword>infection ,</keyword>
	<keyword>immune system ,</keyword>
	<keyword>atherosclerosis</keyword>
</DOC>